Compare ASTH & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTH | TYRA |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2015 | 2021 |
| Metric | ASTH | TYRA |
|---|---|---|
| Price | $23.86 | $37.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $34.00 | ★ $44.63 |
| AVG Volume (30 Days) | 479.2K | ★ 1.2M |
| Earning Date | 03-02-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $519,907,752.00 | N/A |
| Revenue This Year | $27.32 | N/A |
| Revenue Next Year | $10.84 | N/A |
| P/E Ratio | $52.61 | ★ N/A |
| Revenue Growth | ★ 45.90 | N/A |
| 52 Week Low | $18.08 | $6.42 |
| 52 Week High | $34.80 | $38.56 |
| Indicator | ASTH | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 53.05 | 67.37 |
| Support Level | $23.14 | $30.10 |
| Resistance Level | $27.01 | N/A |
| Average True Range (ATR) | 1.35 | 2.30 |
| MACD | 0.06 | 0.19 |
| Stochastic Oscillator | 31.14 | 86.52 |
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.